Effects of Graft Vascular Dimensions on Surgical & Functional Outcomes of

Status Not yet recruiting

Clinical Trial Summary

1. Correlate the radiological and intraoperative measuring of the vascular dimensions, 2. Assess the effect of the vascular dimensions on the short-term surgical complications and 3. Assess the effect of the vascular dimensions on the primary graft function in pediatric and adults KTs.

Clinical Trial Description

Vascular complications after kidney transplantation (KT) are variably rare with an incidence of 3-15%. They are a significant and most serious part of surgical complications of KT. They may acutely result in graft loss during surgery or early in the perioperative period and may threaten patient's life. The most common forms of early vascular complications are haemorrhage, hematomas, arterial or venous thrombosis, arterial vasospasm, and arterial intimal dissection. In pediatric and adult KT, most studies addressing the vascular complications followed a common attitude of estimating the prevalence and management of these complications rather than studying the predisposing factors. Specifically, studying the normal and abnormal anatomy of the grafts has mainly been directed towards the number of graft vessels. However, there are many other vascular parameters that may potentially influence the outcome of vascular anastomosis and therefore the graft and patient outcomes. To the best of the investigators knowledge, the vascular dimensions of the renal and iliac vessels, such as the length, diameter and site of anastomosis to the iliac vessels have not been studied before so the investigators hypothesis that these dimensions can unequally affect the outcomes of surgery and early graft function in KTs. Hence, this study will be conducted to assess the effects of the vascular dimensions on the outcomes of surgery and primary graft function in pediatric versus adult living donor KT. ;

Study Design

Related Conditions & MeSH terms

Kidney Transplant; Complications

Clinical Trial Details

NCT number	NCT05797389
Study type	Observational
Source	Assiut University
Contact	Mohamed L Shehata
Phone	00201093590017
Email	mohamed.l.m.sh@gmail.com
Status	Not yet recruiting
Phase
Start date	April 2023
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04369456` - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients	N/A
Recruiting	`NCT06001320` - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip	Early Phase 1
Withdrawn	`NCT04560582` - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Not yet recruiting	`NCT05782543` - Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion	N/A
Completed	`NCT03996551` - ExeRTiOn2- The Weight Gain Prevention Exercise in Renal Transplant Online Study	N/A
Recruiting	`NCT05081141` - HHV8 and Solid Organ Transplantation
Recruiting	`NCT04508907` - A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients	Phase 4
Recruiting	`NCT06440330` - Define Predictors for Posttransplant Diabetes Mellitus Study
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Recruiting	`NCT04713774` - Bone Density and Vascular Calcifications Evolution After Renal Transplant
Active, not recruiting	`NCT05483725` - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Recruiting	`NCT06095492` - Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus	N/A
Active, not recruiting	`NCT04207177` - Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects	Phase 4
Recruiting	`NCT03410654` - Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.	Early Phase 1
Completed	`NCT03373266` - Serun Fluoride and Kidney Transplant	Phase 2
Completed	`NCT04835948` - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Not yet recruiting	`NCT04514666` - VOCs in Kidney and Liver Transplants	N/A
Recruiting	`NCT03373500` - Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients	N/A
Recruiting	`NCT05900401` - Delayed Tolerance Through Mixed Chimerism	Phase 1/Phase 2
Not yet recruiting	`NCT05166460` - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of Graft Vascular Dimensions on Surgical and Functional Outcomes of Living Donor Kidney Transplantation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms